PARIS, Jan. 14, 2025 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has…Read More
You might also be interested in reading Solana (SOL) Continues Sideways Move As Outflows Record $39 Million.